Related Experiment Video
Updated: Aug 6, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
The effect of temperament and character on response to selective serotonin reuptake inhibitors in panic disorder
C Marchesi1, A Cantoni, S Fontò
1Department of Neuroscience, Psychiatric Division, University of Parma, Parma, Italy. carlo.marchesi@unipr.it
Objective:
In this prospective study, temperament and character were evaluated in patients with panic disorder (PD), before 1 year of medication therapy, to verify whether these factors influenced the outcome of treatment.
Method:
Seventy-one PD patients were evaluated with the SCID-IV, the Temperament and Character Inventory (TCI), the SCL-90, the Ham-A and the Ham-D. Patients were treated with pharmacotherapy and were evaluated monthly over 1 year.
Results:
Before treatment, non-remitted patients showed higher levels of harm avoidance (HA) and lower levels of persistence (P), self-directedness (SD) and cooperativeness (C), whereas remitted patients showed only higher levels of HA. After controlling the effect of the confounding variables, the likelihood to achieve remission was positively related to SD score (OR = 1.12; P = 0.002), particularly 'self-acceptance' SD dimension (OR = 1.30; P = 0.02).
Conclusions:
Our data suggest that in PD: i) the evaluation of personality, using the Cloninger's model, confirms the presence of personality pathology as one predictor of non-response to treatment; ii) in patients with low SD a combination of medication and cognitive-behaviour therapy should be the most effective treatment.
Related Concept Videos
Panic Disorder
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Personality Theory by Eysenck and Eysenck
In the extroversion/introversion dimension, highly extroverted people are sociable, outgoing, and easily connect with others. In contrast,...
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
